Unrivalled in its field, Martindale provides practical, evidence-based, global guidance, allowing you to quickly understand the characteristics of drugs and other pharmaceutical substances and their clinical uses.
Sales and UpgradesContent Updates
Global source of information: International, multi-lingual coverage, including synonyms, drug and chemical identifiers, chemical formulae, structures and pharmacopeial standards
Breadth of content: Expertly curated data on over 248,000 medicines provides an unparalleled, consolidated database of preparations
Range of drugs: Provides concise and accurate information on herbals, diagnostic agents, radiopharmaceuticals, pharmaceutical excipients, toxins and poisons
Reviewed and updated every 3 months by expert teams
*based on average data in the last 12 months
This update contains 5 new monographs. Preparations have been updated for 2 countries.
New monographs:
• Avapritinib is a tyrosine kinase inhibitor used in the treatment of gastrointestinal stromal tumours and systemic mastocytosis.
• Difelikefalin is a kappa-opioid receptor agonist used in the management of moderate to severe pruritus associated with chronic kidney disease in haemodialysis patients.
• Inclisiran is a double-stranded, small interfering ribonucleic acid (siRNA) conjugate used in the management of heterozygous familial and non-familial hypercholesterolaemia and mixed dyslipidaemia.
• Ozanimod is an immunomodulator used in the treatment of relapsing forms of multiple sclerosis and ulcerative colitis.
• Upadacitinib is an orally active Janus kinase inhibitor used in the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and atopic eczema.
Updated names, synonyms and codes; official standards; official preparations:
• Entries for the European Pharmacopoeia have been updated for Ph Eur 10
Proprietary Preparations and Manufacturers updated for the following countries and regions:
• UK†
• USA†
† Countries updated on an ongoing basis
This update contains 3 new monographs. Preparations have been updated for 7 countries.
New monographs:
• Bempedoic acid is an ACL inhibitor used in the management of primary hypercholesterolaemia, mixed dyslipidaemia, and atherosclerotic cardiovascular disease.
• Filgotinib is an orally active Janus kinase (JAK) inhibitor used as a disease-modifying antirheumatic drug (DMARD) in the treatment of moderately to severely active rheumatoid arthritis.
• Risdiplam is a disease-modifying therapy that increases production of functional survival motor neuron protein and is used in the treatment of spinal muscular atrophy.
Proprietary Preparations and Manufacturers updated for the following countries and regions:
• Czech Republic
• Finland
• Netherlands
• South Africa
• Thailand
• UK†
• USA†
† Countries updated on an ongoing basis
This update contains 3 new monographs. Preparations have been updated for 9 countries.
New monographs:
• Brolucizumab, a recombinant humanised monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A), is used for the treatment of neovascular (wet) age-related macular degeneration.
• COVID-19 vaccines are used for active immunisation against COVID-19 disease.
• Enfortumab vedotin is an antibody-drug conjugate used for the treatment of locally advanced or metastatic urothelial cancer.
Notable revisions:
• New treatment review for COVID-19 infection.
Updated names, synonyms and codes; official standards; official preparations:
• Entries for the British Pharmacopoeia have been updated for BP 2020 and BP (Vet) 2020.
Proprietary Preparations and Manufacturers updated for the following countries and regions:
• Belgium
• India
• Ireland
• Norway
• Philippines
• UAE
• UK†
• USA†
• Venezuela
† Countries updated on an ongoing basis
This update contains 3 new monographs and 1 existing monograph has been updated. Preparations have been updated for 4 countries.
New monographs:
• Elapegademase is a recombinant form of the pegylated enzyme adenosine deaminase (pegademase). It is used in the treatment of severe combined immunodeficiency disease associated with a deficiency of adenosine deaminase.
• Lefamulin is a pleuromutilin antibacterial used for the treatment of community-acquired bacterial pneumonia.
• Vestronidase alfa is a recombinant human lysosomal beta-glucuronidase used as enzyme replacement therapy for the treatment of the non-neurological manifestations of mucopolysaccharidosis VII.
Notable revisions:
• Dexamethasone is being tried in the treatment of COVID-19 (coronavirus disease 2019) infection.
Updated names, synonyms and codes; official standards; official preparations:
• Entries for USP and USNF have been updated for USP 43-USNF 38
Proprietary Preparations and Manufacturers updated for the following countries and regions:
• Brazil
• Hong Kong
• UK†
• USA†
† Countries updated on an ongoing basis
This update contains 5 new monographs and 1 existing monograph has been updated. Preparations have been updated for 7 countries.
New monographs:
• Crizanlizumab is a human immunoglobulin G2 monoclonal antibody, that binds to P-selectin, used to reduce the frequency of vaso-occlusive crises in sickle-cell disease.
• Elexacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) protein corrector used with ivacaftor and tezacaftor in the treatment of cystic fibrosis in patients who have at least one F508del mutation in the CFTR gene.
• Lumateperone is an atypical antipsychotic used for the treatment of schizophrenia.
• Teprotumumab is a recombinant human monoclonal antibody, directed against the insulin-like growth factor-1 receptor, used for the treatment of thyroid eye disease (Graves’ ophthalmopathy).
• Trifarotene is a retinoid analogue used topically in the treatment of acne vulgaris of the face and body.
Notable revision:
• Eltrombopag is used with standard immunosuppressive therapy for the first-line treatment of patients aged 2 years and older with severe aplastic anaemia.
Proprietary Preparations and Manufacturers updated for the following countries and regions:
• Argentina
• Australia
• Greece
• Malaysia
• Portugal
• USA†
• UK†
† Countries updated on an ongoing basis
This update contains 5 new monographs. Preparations have been updated for 7 countries.
New monographs:
• Cefiderocol is a siderophore cephalosporin approved for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.
• Givosiran, a small interfering RNA, that is used in the treatment of acute hepatic porphyria.
• Lasmiditan is a selective serotonin agonist and can be used to treat acute migraine.
• Luspatercept is a recombinant fusion protein that acts as an erythroid maturation agent. It is used to treat transfusion-dependent anaemia associated with beta-thalassaemia or myelodysplastic syndromes.
• Voxelotor is a haemoglobin oxygen-affinity modulator in the management of sickle-cell disease.
Proprietary Preparations and Manufacturers updated for the following countries and regions:
• Hungary
• Indonesia
• New Zealand
• Russia
• Turkey
• USA†
• UK†
† Countries updated on an ongoing basis
